CG
SCLN

Cutler Group’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Cutler Group’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,300
Closed -$1K – 7617
2017
Q1 		$1K Buy
7,300
+2,000
+38% +$20K ﹤0.01% 6211
2016
Q4 		$7K Buy
+5,300
New +$53K ﹤0.01% 4685

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cutler Group's SCLN Position: Q3 2017 in Review

Cutler Group sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 897 shares — an estimated $9K sold.

Cutler Group first reported a position in SCLN in Q4 2015 and held it in 7 quarters. The position peaked at $54K in Q2 2016. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Cutler Group reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Cutler Group sold 897 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $9K.
  • Cutler Group first reported a position in Sciclone Pharmaceuticals Inc in Q4 2015 and held it in 7 quarters.
  • Cutler Group's Sciclone Pharmaceuticals Inc position peaked at $54K in Q2 2016.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Cutler Group's 13F filing for Q3 2017, filed 17 Oct 2017.